Abstract
Surveillance studies for Covid-19 prevalence estimation are subject to sampling bias due to oversampling of symptomatic individuals and error-prone tests, particularly rapid antigen tests which are known to have high false negative rates for asymptomatic individuals. This results in naïve estimators which can be very far from the truth.In this work, we present a method that removes these two sources of error directly. Moreover, our procedure can be easily extended to the stratified error situation in which a test has very different error rate profiles for symptomatic and asymptomatic individuals as is the case for rapid antigen testing. The result is an easily understandable four-step algorithm that produces much more reliable prevalence estimates as demonstrated on data from the Israeli Ministry of Health. Thus it may re-open the debate about whether we are under-valuing rapid testing as a surveillance tool and may have policy implications in Third-World countries or disadvantaged communities where access to PCR testing may be less accessible.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data can be retrieved from https://github.com/nshomron/covidpred, and it is publicly available.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data can be retrieved from https://github.com/nshomron/covidpred, and it is publicly available.
